Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (6)
Language
- English (6) (remove)
Keywords
- angiogenesis (2)
- cancer (2)
- Listeria monocytogenes (1)
- Lung cancer (1)
- Lungenkrebs (1)
- Malignant effusion (1)
- Oncolytic vaccinia virus (1)
- Oncolytic virotherapy (1)
- VEGF (1)
- Vascular endothelial Growth Factor (1)
- antibodies (1)
- antibody production (1)
- breast-tumors (1)
- cancer treatment (1)
- canine cancer cell lines (1)
- canine cancer therapy (1)
- canine soft tissue sarcoma (CSTS) (1)
- carcinomas (1)
- cell cultures (1)
- endothelial growth-factor (1)
- enzyme-linked immunoassays (1)
- humanized tumor (1)
- microenvironment (1)
- microvascular density (1)
- model (1)
- mouse model (1)
- nude-mice (1)
- oncolytic virus (1)
- oncolytic viruses (1)
- pet dogs (1)
- subcutaneous human tumors (1)
- therapy (1)
- vaccinia virus (1)
- viral replication (1)
Institute
Oncolytic vaccinia virus (VACV) therapy is an alternative cancer treatment modality that mediates targeted tumor destruction through a tumor-selective replication and an induction of anti-tumor immunity. We developed a humanized tumor mouse model with subcutaneous human tumors to analyze the interactions of VACV with the developing tumors and human immune system. A successful systemic reconstitution with human immune cells including functional T cells as well as development of tumors infiltrated with human T and natural killer (NK) cells was observed. We also demonstrated successful in vivo colonization of such tumors with systemically administered VACVs. Further, a new recombinant GLV-1h376 VACV encoding for a secreted human CTLA4-blocking single-chain antibody (CTLA4 scAb) was tested. Surprisingly, although proving CTLA4 scAb’s in vitro binding ability and functionality in cell culture, beside the significant increase of CD56\(^{bright}\) NK cell subset, GLV-1h376 was not able to increase cytotoxic T or overall NK cell levels at the tumor site. Importantly, the virus-encoded β-glucuronidase as a measure of viral titer and CTLA4 scAb amount was demonstrated. Therefore, studies in our “patient-like” humanized tumor mouse model allow the exploration of newly designed therapy strategies considering the complex relationships between the developing tumor, the oncolytic virus, and the human immune system.